Bayer First-Half Boosted By Favorable Currencies

19 August 1997

German drugs and chemicals major Bayer AG posted first-half 1997 resultswhich at first disappointed analysts and investors, who later saw underlying strength in the figures; the firm's shares fell at first but recovered.

Bayer group sales for the period rose 11% to 27.4 billion Deutschemarks ($14.94 billion), with 1.3 billion marks attributed to favorable currency exchange rates, 1.7 billion marks to higher volumes and 300 million marks to newly-acquired businesses. Group profits increased 13% to 1.7 billion marks, and there was a significant rise in cash flow of 18% to 3.2 billion marks, the company revealed.

Full-Year Sales Forecast Of Over 50 Billion DM For the second half of the year, Bayer says it expects the "lively demand to continue and exchange rates, especially that of the US dollar, to remain stable." The company adds that it is "confident that sales for the full year will exceed 50 billion marks, and that the net income will show an increase over 1996."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight